RAFAEL HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.705 USD | -0.29% |
|
-3.12% | -6.83% |
| Sales 2022 | 410K 34.18M | Sales 2023 | 279K 23.26M | Capitalization | 48.59M 4.05B |
|---|---|---|---|---|---|
| Net income 2022 | -125M -10.42B | Net income 2023 | -1M -83.38M | EV / Sales 2022 | 90.2 x |
| Net cash position 2022 | 11.54M 962M | Net cash position 2023 | 21.5M 1.79B | EV / Sales 2023 | 97.1 x |
| P/E ratio 2022 |
-0.32
x | P/E ratio 2023 |
-24.8
x | Employees | 13 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 76.32% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.29% | ||
| 1 week | -3.12% | ||
| Current month | -0.87% | ||
| 1 month | -0.29% | ||
| 3 months | -4.75% | ||
| 6 months | +12.91% | ||
| Current year | -6.83% |
1 week
1.65
1.84
1 month
1.651.89
Current year
1.621.95
1 year
1.442.52
3 years
1.4466.44
5 years
1.4466.44
10 years
1.4466.44
| Managers | Title | Age | Since |
|---|---|---|---|
William Conkling
CEO | Chief Executive Officer | 53 | 15/21/15 |
David Polinsky
DFI | Director of Finance/CFO | 53 | 01/17/01 |
Howard Jonas
CHM | Chairman | 68 | 17/17/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Howard Jonas
CHM | Chairman | 68 | 17/17/17 |
| Director/Board Member | 80 | 26/18/26 | |
Michael Weiss
BRD | Director/Board Member | 73 | 01/18/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.705 | -0.29% | 15,210 |
| 25/24/25 | 1.71 | 0.00% | 7,625 |
| 24/24/24 | 1.71 | 0.00% | 4,206 |
| 23/24/23 | 1.71 | -1.72% | 8,463 |
| 22/24/22 | 1.74 | -1.14% | 6,981 |
Delayed Quote Nyse, April 27, 2024 at 01:40 am IST
More quotes
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.
Calendar
11/06/2024
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.83% | 41.92M | |
| +36.16% | 27.94B | |
| -13.74% | 26.97B | |
| +25.00% | 26.95B | |
| -0.71% | 25.32B | |
| +44.49% | 22.58B | |
| +2.78% | 19.59B | |
| +1.45% | 19.52B | |
| +28.54% | 16.23B | |
| -14.80% | 14.98B |
- Stock Market
- Equities
- RFL Stock
